Immunomodulatory and therapeutic properties of FK-565 in mice

James E. Talmadge, Barbara Lenz, Mark Schneider, Hamblin Phillips, Cedric Long

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalCancer Immunology Immunotherapy
Volume28
Issue number2
DOIs
StatePublished - Feb 1 1989

Fingerprint

Natural Killer Cells
Macrophages
Therapeutics
Immunologic Factors
FK 565
Neoplasm Metastasis
T-Lymphocytes
Peptides
In Vitro Techniques

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Immunomodulatory and therapeutic properties of FK-565 in mice. / Talmadge, James E.; Lenz, Barbara; Schneider, Mark; Phillips, Hamblin; Long, Cedric.

In: Cancer Immunology Immunotherapy, Vol. 28, No. 2, 01.02.1989, p. 93-100.

Research output: Contribution to journalArticle

Talmadge, James E. ; Lenz, Barbara ; Schneider, Mark ; Phillips, Hamblin ; Long, Cedric. / Immunomodulatory and therapeutic properties of FK-565 in mice. In: Cancer Immunology Immunotherapy. 1989 ; Vol. 28, No. 2. pp. 93-100.
@article{b3b6275306e4400ca09ecf83718e6dda,
title = "Immunomodulatory and therapeutic properties of FK-565 in mice",
abstract = "The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.",
author = "Talmadge, {James E.} and Barbara Lenz and Mark Schneider and Hamblin Phillips and Cedric Long",
year = "1989",
month = "2",
day = "1",
doi = "10.1007/BF00199108",
language = "English (US)",
volume = "28",
pages = "93--100",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Immunomodulatory and therapeutic properties of FK-565 in mice

AU - Talmadge, James E.

AU - Lenz, Barbara

AU - Schneider, Mark

AU - Phillips, Hamblin

AU - Long, Cedric

PY - 1989/2/1

Y1 - 1989/2/1

N2 - The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.

AB - The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.

UR - http://www.scopus.com/inward/record.url?scp=0024496171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024496171&partnerID=8YFLogxK

U2 - 10.1007/BF00199108

DO - 10.1007/BF00199108

M3 - Article

C2 - 2521814

AN - SCOPUS:0024496171

VL - 28

SP - 93

EP - 100

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -